GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

151.3B

Vuru Grade

75.00/100

Current Price

$100.30
-0.81 (-0.80%)

Growth Price

$26.98
Overvalued by 73.10%

Stability Price

$15.14
Overvalued by 84.90%

Company Metrics

  • 18.01 P/E
  • 7.37 P/S
  • 11.26 P/B
  • 5.613 EPS
  • 39.33% Cash ROIC
  • 0.34 Cash Ratio
  • 0 / 0% Dividend
  • 15.51M Avg. Vol.
  • 1.69B Shares
  • 151.3B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Gilead Sciences Inc. Just Paid $125 Million for Something It Can't Use for a Year
Motley Fool - Nov 24, 2014
Talk about having cash burning a hole in your pocket. Gilead Sciences (NASDAQ: GILD ) spent $125 million of the $6.2 billion it had in the bank at the end of the third quarter to buy a priority review voucher from Canada's Knight Therapeutics.
Why You Shouldn't Bet Against Gilead Sciences (GILD) Stock - Tale of the Tape - Nasdaq
Investors Should Be Concerned About Gilead (GILD) - Seeking Alpha
Why You Shouldn't Worry About Gilead Sciences, Inc.
Motley Fool - Oct 30, 2014
It shouldn't be too shocking to learn that sales of Gilead Sciences' (NASDAQ: GILD ) mega blockbuster Sovaldi sagged in the third quarter.
Most Active Weekly Options: Gilead Sciences, Inc. (GILD) - Schaeffers Research (blog)
Gilead Sciences: Even More Attractive After Third Quarter Results (GILD) - Seeking Alpha (registration)
Should Gilead Sciences, Inc. Pay a Dividend?
Nasdaq - Nov 26, 2014
Given that the company's revenue has more than doubled in 2014 compared with a year ago, Gilead should have the resources to pay a dividend on the back of its hepatitis C franchise.
Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So ...
Motley Fool - Nov 11, 2014
It's hard for any new hepatitis C drugs to compete with Gilead Sciences' (NASDAQ: GILD ) Harvoni, with its cure rate topping 95%, especially when you consider that some of those uncured patients are the inevitable dropouts who can be found in every ...
Gilead Sees Large Insider Stock Sale Into Debt Offering - 24/7 Wall St.
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of ... - MarketWatch
2 More Gilead Sciences, Inc. Blockbusters You Ought to Know About
Motley Fool - Nov 3, 2014
Gilead Sciences (NASDAQ: GILD ) hepatitis C drugs may be capturing all the attention, but its Gilead's HIV drug franchise that's been responsible for the company's long-standing success. Gilead is racking up billions in global revenue thanks to a slate ...
Is This Trend Making Gilead Sciences, Inc. Worry?
Motley Fool - Nov 5, 2014
If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead's (NASDAQ: GILD ) Harvoni, you expect that your insurer will pay for it. But that isn't happening in all ...
Gilead: Stay The Course (GILD) - Seeking Alpha (registration)
Gilead Sciences In Correction Mode
Benzinga - Nov 13, 2014
Gilead Sciences, Inc. (NASDAQ: GILD) had been on a rocket ship ride up until September, rising from the $60s to over $100 since April.
Sealed Air Corp (SEE), Louisiana-Pacific Corporation (LPX), Gilead Sciences ... - Tech Insider
Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape - Nasdaq
Gilead Sciences Harvoni Has A Better-Than-Expected Launch
Bidness ETC - Nov 24, 2014
However, the company saw its shares drop Thursday on the back of rumors that Carl Icahn had accumulated a sizeable stake in the company. This had shareholders worried that the activist investor might soon launch an agenda, asking the company to look ...
Weekly CFO Sells Highlight: Tableau Software Inc, Gilead Sciences Inc ...
GuruFocus.com - Nov 17, 2014
According to GuruFocus Insider Data, the recent CFO sales were: Tableau Software Inc, Gilead Sciences Inc, and Facebook Inc. Tableau Software Inc. (DATA): CFO Thomas E Walker Jr sold 10,000 shares.
Trade of the Day: Gilead Sciences Stock on Sale
Investorplace.com - Nov 18, 2014
Gilead Sciences, Inc. (GILD) - I last reviewed this stock on Oct. 28, at $113.25, but it has been featured as the Trade of the Day numerous times over the past two years.
Dispelling Some Of The Myths Surrounding Gilead Sciences - Seeking Alpha (registration)
European Commission Grants Marketing Authorization for Gilead's Harvoni ... - MarketWatch